Savara (NASDAQ:SVRA) is a biopharmaceutical company engaged in developing and commercializing treatments for rare respiratory diseases. Through its robust pipeline, Savara aims to address unmet medical needs in conditions such as Pulmonary Alveolar Proteinosis (PAP), where the company has made significant strides with its flagship product Molgradex. The company's projects demonstrate a deep scientific understanding and a commitment to innovation in respiratory care, focusing on improving patient outcomes and quality of life. Savara's objective is to become a leader in rare respiratory diseases by advancing its research, expanding its product portfolio, and reaching patients worldwide who suffer from these debilitating conditions.